Prospective Validation of an AI Model for Predicting Liver Metastasis in Colorectal Cancer

Summary

This is a prospective, multicenter, observational study designed to validate the predictive accuracy of a pre-developed multimodal deep learning model. The model integrates preoperative contrast-enhanced CT scans, digitized postoperative pathology images, and standard clinical data to estimate the risk of liver metastasis within two years after curative surgery in patients with stage I-III colorectal cancer. The primary objective is to evaluate the model's performance in an independent, prospectively enrolled patient cohort. Participants will receive standard-of-care treatment according to clinical guidelines. The study involves no experimental interventions; it solely involves the collection and analysis of routinely generated clinical data. The goal is to assess the model's potential for clinical translation by providing a reliable tool for stratifying patients' risk of liver metastasis, which could inform personalized surveillance strategies.

Eligibility

Inclusion Criteria:

* Age 18-75 years, any gender.
* Clinical diagnosis of primary colon or rectal adenocarcinoma (Stage I-III). Scheduled to undergo curative radical resection for colorectal cancer.
* Preoperative contrast-enhanced abdominal/pelvic CT scan performed within 1 month before surgery, with acceptable image quality.
* No evidence of distant metastasis (including synchronous liver metastasis) on preoperative examination.
* ECOG Performance Status of 0 or 1.
* Patient or their legal representative voluntarily participates and provides written informed consent.

Exclusion Criteria:

* Postoperative pathological confirmation of non-primary colorectal adenocarcinoma or presence of distant metastasis.
* Intraoperative determination of non-R0 resection, or performance of palliative surgery/ostomy only.
* History of other malignant tumors.
* Previous history of liver surgery or liver transplantation.
* Death within the perioperative period (within 30 days after surgery).
* Refusal to participate in follow-up, withdrawal of informed consent, or loss to follow-up.

Conditions3

Browse More Trials